Date: 2012-01-25
Type of information: Fundraising
Company: Targovax (Norway)
Investors: Radium Hospital Research Foundation (Norway) - Birk Venture (Norway) - RO Invest (Norway) - existing owners
Amount: 18.5 million NOK (€2.41 million)
Funding type: financing round
Planned used: This financing will enable Targovax to submit an application for clinical studies, and to produce the TG01, a cancer vaccine directed towards pancreatic cancer, according to pharmaceutical standards. The company plans to be ready to include the first patients in the last quarter of 2012.
Others: Targovax has secured almost 13 MNOK in private capital from the Radium Hospital Research Foundation, Birk Venture, RO Invest and existing owners for further development of the cancer vaccine TG01 within pancreatic cancer.
Therapeutic area: Cancer - Oncology
